Mouse studies have shown that mTOR inhibitors such as Rapamycin, which formerly received FDA approval for cancer treatments, successfully rescued deficiencies in social and repetitive behaviors in postnatal day 7 TSC-mutant mice, and only social deficits in 6-week-old TSC-mutant mice [118, 119]. This evidence concerns the gene MTOR and cancer.